奥麦罗制药

$奥麦罗制药(OMER)$ SCHEDULE 13G/A [Amend] Statement of Beneficial Ownership by Certain Investors Accession Number: 0000102909-26-001922  Act: 34  Size: 7 KB 网页链接

$奥麦罗制药(OMER)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-26-001280  Size: 10 KB 网页链接

$奥麦罗制药(OMER)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0001437749-26-010634  Act: 34  Size: 462 KB 网页链接

$奥麦罗制药(OMER)$ 144 Report of proposed sale of securities Accession Number: 0001950047-26-000358  Act: 33  Size: 5 KB 网页链接

$奥麦罗制药(OMER)$ 144 Report of proposed sale of securities Accession Number: 0001950047-26-000386  Act: 33  Size: 5 KB 网页链接

$奥麦罗制药(OMER)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0001437749-26-004950  Size: 11 KB 网页链接

$奥麦罗制药(OMER)$ 8-K Current report, item 2.02 Accession Number: 0001437749-26-000820  Act: 34  Size: 154 KB 网页链接

$奥麦罗制药(OMER)$ Vanguard Group, Inc. 报告持有 Omeros Corp 普通股 4,013,315 股，占该类别股份的 5.66%。此次申报是由于 Vanguard Group, Inc. 内部重组而进行的更新，截至 2026 年 1 月 12 日，此后某些子公司将分别报告实益所有权。这些股份是在正常业务过程中获得和持有的，并非为了影响...

$奥麦罗制药(OMER)$ 10-K Annual report [Section 13 and 15(d), not S-K Item 405] Accession Number: 0001437749-26-010636  Act: 34  Size: 13 MB 网页链接

$奥麦罗制药(OMER)$ SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors Accession Number: 0000102909-26-000206  Act: 34  Size: 6 KB 网页链接